clinical trial · NCT05921929
First-In-Human (FIH), Single Ascending Dose (SAD) Study of FluoroEthylNorMemantine (FENM)
PTSDAlzheimer DiseaseBrain DiseasesNeuro-Degenerative DiseaseMajor Depressive DisorderTreatment Resistant DepressionFluoroethylnormemantine (FENM)
brief summary
The goal of this First-In-Human (FIH) trial is to learn about safety and PharmacoKinetics (PK) in healthy adult volunteers. The main questions it aims to answer are: * What is the safety of single ascending doses of the FluoroEthylNorMemantine (FENM)? * What is the PK profile of single ascending doses of the FENM in human? * What is the preliminary exploratory time course of Brain Disease Neurotrophic Factor (BDNF) plasmatic levels of single ascending doses of the FENM? Participants will receive one single oral dose of FENM.
started
May 2, 2024
primary completion
May 2, 2024
completion
May 2, 2024
last updated
May 3, 2024
official title
Safety and Pharmacokinetics of a Novel NMDA Receptor Antagonist Against Brain Related Diseases in Healthy Adult Volunteers: First-in-human, Phase I, Single Dose-escalating, Open Label Study
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol